RxDoctor Payments Data

Ethan Gore, MD

Neurology · Pensacola, FLNPI 1003136987

Payments from drug & device makers

$46,138in general payments, 2019–2025

Across 749 payments — averaging $61.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Biogen$11K
  • Eisai Inc.$4K
  • Novartis$905
  • Teva Pharmaceuticals USA, Inc.$863
  • SK Life Science, Inc.$728
  • plus $6K from 45 others

What the payments were for

  • Consulting fees$3,8408%
  • Speaking & faculty fees$28,84663%
  • Travel & lodging$3991%
  • Food & beverage$13,03628%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,138 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$434,762
Medicare patients
808
Services billed
11,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5019$401,964
Emgality PenGalcanezumab-Gnlm44$68,884
GlatopaGlatiramer Acetate12$42,930
MyrbetriqMirabegron48$39,445
RexultiBrexpiprazole11$24,308
AptiomEslicarbazepine Acetate15$21,291
FycompaPerampanel14$21,218
BriviactBrivaracetam11$18,319
RytaryCarbidopa/Levodopa12$17,214
Rivastigmine39$15,308
Rufinamide11$10,493
Duloxetine Hcl192$6,111
Memantine Hcl181$5,843
Donepezil Hcl358$5,587
Carbamazepine ErCarbamazepine57$5,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$109$24,30811 claims
Sunovion Pharmaceuticals Inc.Aptiom$218$21,29115 claims
Eisai Inc.Fycompa$4,301$21,21814 claims
UCB, Inc.Briviact$328$18,31911 claims
Amneal Pharmaceuticals LLCRytary$170$17,21412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →